In brief
- Arizona is allocating $5 million from the state Department of Health to an ibogaine clinical trial.
- The study, led by the Barrow Neurological Institute, will evaluate the substance for chronic traumatic brain injury (TBI).
- It will be a randomized, placebo-controlled phase 1/2 trial with 40 participants; recruitment will begin in 2027.
The Arizona Department of Health has awarded $5 million to the Barrow Neurological Institute in Phoenix to launch a clinical trial investigating ibogaine as a potential treatment for the persistent symptoms of traumatic brain injury (TBI). The announcement, made public on August 5, makes Arizona the second U.S. state, following Texas, to allocate large-scale public funding for clinical research into this plant-derived substance.
A trial designed with standard pharmaceutical rigor
The phase 1/2 study will be led by neuropsychiatrist Anna Burke alongside a multidisciplinary team at Barrow, in collaboration with the Barrow Neuro Analytics Center and Arizona State University (ASU). It will recruit 40 people with chronic symptoms resulting from a TBI, who will be randomly assigned to receive ibogaine or a placebo in a double-blind design—the standard method for separating the substance’s actual effect from the placebo effect. According to Barrow, the first participant will be enrolled in 2027, meaning results will not be available until well into that year or the next.
The funding comes from a line item approved in the 2025 Arizona state budget, championed by former Senator Kyrsten Sinema after she heard testimonies from veterans who had traveled outside the U.S. to receive the treatment.
Why TBI and the interest behind it
Susan Criswell, medical director of clinical research at Barrow, notes that approximately half of the people who suffer a traumatic brain injury experience lingering symptoms or incomplete recovery beyond six months—a therapeutic gap that current options address poorly. Interest in ibogaine in this field is supported by previous open-label, non-controlled studies involving U.S. veterans with both TBI and post-traumatic stress, in which a single dose was associated with sustained improvements in symptoms, cognitive function, and quality of life. In the U.S., ibogaine remains classified as a Schedule I substance, the same category as heroin or LSD, which has until now driven those seeking treatment to clinics in Mexico and other countries. The Arizona trial joins a $50 million allocation approved in Texas in 2025 and an executive order signed in April by the Trump Administration that directs another $50 million toward psychedelic research.
What this implies
This is still a very early-phase trial: it has not yet begun recruiting, and its first data will not arrive before 2028. The evidence supporting it comes primarily from open-label, unblinded studies with small sample sizes that do not rule out the effect of expectations. Furthermore, ibogaine requires careful cardiac monitoring due to its potential to prolong the QT interval, a matter that neither Barrow nor the press releases consulted have detailed yet for this specific trial. Regardless of the final outcome, a public agency allocating millions to formally study a substance previously relegated to unregulated clinics is a step toward generating the data that is currently missing.
Related previous coverage: Colorado opens the door to regulated ibogaine starting in August.
Source
- Barrow Neurological Institute. Arizona Grants $5M to Barrow for Clinical Trial of Ibogaine in TBI. Barrow Neurological Institute, August 5, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
